NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









LigaChem Biosciences

LigaChem Biosciences

Daejeon, Daejeonligachembio.com

Overview

A publicly-traded, clinical-stage biopharmaceutical company that specializes in the discovery and development of medicines, with a focus on its proprietary antibody-drug conjugate (ADC) platform technology. The company was founded in 2006 and changed its name from LegoChem Biosciences in April 2024.

Portfolio Companies

2

Investments

LigaChem Biosciences investments
CompanyDateStageLead
1ST Biotherapeutics, Inc.Jan 2026Series DCo-investor
Iksuda TherapeuticsJun 2025StrategicLead
Iksuda TherapeuticsMar 2025Corporate FundingLead
Iksuda TherapeuticsNov 2024StrategicLead

Sector & Stage Mix

Industry, funding stage, and valuation band breakdowns.

Premium
SeedSeries ASeries BGrowth

Unlock portfolio analytics

Sign up to view full sector, stage, and valuation breakdowns for this investor.

Investment Activity

Yearly cadence, pace, and funding raised over time.

Premium
2021
2022
2023
2024
2025
2026

Unlock portfolio analytics

Sign up to explore yearly investment trends and funding raised over time.

FAQ

Firmographic Details

HeadquartersDaejeon, Daejeon
Year FoundedN/A

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.